LifeStance's 15% Margin Is Real; the 2027 EHR Drag Is the Bill

A 25% growth quarter and a second straight 15% EBITDA margin came with the first hard number for next year's EHR revenue hit — and a stock already near its highs.

LFST · Earnings Call · 2026-11-05

The beat is real — and the margin inflection is now in the numbers

LifeStance did not just beat; it crossed a threshold. Revenue rose 25% to $456 million, visit volumes climbed 17% to 2.7 million, and total revenue per visit increased 7% to $170. Adjusted EBITDA jumped 70% to $68 million, a 15% margin — the second consecutive quarter at that level. Net income was $22 million, a $21 million improvement, and free cash flow was $22 million. That is a different company from the one that spent years burning cash and defending its model. The last filed quarter shows total revenue of $435 million, up 26% year over year, while operating margin reached 7.0%, up 8.8 percentage points. Total revenue of $435 million, +26% y/y Operating margin of 7.0%, +8.8pp y/y The tape has noticed: LFST is up 17.5% over 90 days and sits within 5.5% of its recent high, even though it remains 53.6% below its 2021 peak.CEO David Bourdon framed it as broad-based: “For the second consecutive quarter, we had revenue growth of 25% or more and adjusted EBITDA margins of 15%.” — David Bourdon, Chief Executive Officer · 2026-11-05 The engine is still the clinician value proposition: 8,863 clinicians, up 11%, with 321 net adds in the quarter. Productivity rose 5% even against a tough prior-year comparison. That combination — more clinicians and fuller calendars — is what drives patient access and operating leverage at the same time.

What actually changed: the EHR bill gets a revenue line

The new information in this call is not the EHR itself. LifeStance has been telegraphing a new EHR for a year. In August, Bourdon called it “foundational for us. It's going to enable future success for LifeStance.” — David Bourdon, Chief Executive Officer · 2026-08-06 He also warned of “a little bit of a short-term blip in productivity” — David Bourdon, Chief Executive Officer · 2026-08-06 during the rollout. What was missing was a number. On this call, CFO Ryan McGroarty supplied one:

we expect a temporary impact from the implementation of a new EHR, which we estimate will impact 2027 revenue growth by approximately 1 to 2 percentage points.
Ryan McGroarty, Chief Financial Officer · 2026-11-05

That pushes 2027 growth to the lower end of the long-term mid-teens range. The cost range — $20 million to $30 million, split between EBITDA adjustment and capitalization — was already disclosed last year. The revenue hit is the fresh piece, and it matters because it lands precisely when the market is trying to underwrite the next leg of margin expansion.Management is framing this as a classic investment year: phased rollout, first state, a couple hundred clinicians, full implementation by year-end 2027, no carryover into 2028. “the expectation around EHR implementation will be roughly between $20 million and $30 million, which would be either an adjustment to EBITDA or capitalized.” — Ryan McGroarty, Chief Financial Officer · 2026-11-05 The EHR implementation is real work, and the logic is plausible: better interoperability, fewer point solutions, faster scheduling, and a cleaner data layer for AI. AI capabilities are part of the pitch. But it is also a self-inflicted air pocket in a stock that has already re-rated. Investors are being asked to look through 1-2 points of growth to a 2028 payoff that management will not formally quantify until early 2028.

The conservative tells: margins, retention, and specialty

The most interesting tension is margin. LFST is already at 15% adjusted EBITDA, the low end of its long-term 15%-20% target. Analyst Jack Slevin asked why the company cannot go higher. McGroarty's answer was deliberately unhelpful: “the 15% to 20% of adjusted EBITDA on a long-term basis, but really with the 20% not representing a ceiling.” — Ryan McGroarty, Chief Financial Officer · 2026-11-05 He then said management will not refine the long-term algorithm until early 2028. That is either disciplined sandbagging or a signal that the easy margin leverage is behind them. The numbers suggest the former is at least possible: free cash flow less stock comp was $68 million in the latest filed quarter, a 15.7% margin, and effective net cash has improved to -$64 million from -$230 million two years ago. Free cash flow less SBC of $68 million Effective net cash of -$64 millionRetention is the quieter question. The company added 321 clinicians, but Bourdon admitted: “retention has been stable. So we have not seen an uptick or downtick.” — David Bourdon, Chief Executive Officer · 2026-11-05 The retention level is still an opportunity — management thinks it can improve by 5-plus percent over the long run, with the weakest cohort being new clinicians. That is not a crisis; stable retention plus strong recruiting is a valid growth model. But it means the clinician retention story is still a promise, not a proven accelerant.Specialty is the most tangible new growth lever. Bourdon said: “all of our specialty service comprised of about $50 million of revenue last year. It's going to grow 40% this year to roughly $70 million.” — David Bourdon, Chief Executive Officer · 2026-11-05 That is meaningful relative to a ~$1.75 billion revenue base, but still only about 4%. The Specialty Services rollout — TMS at 37 centers, Spravato at 25 — is deliberately slow, a handful per quarter. The upside is real if payer reimbursement broadens; the risk is that it remains a small, high-acuity niche rather than a second growth engine.

Why the stock can still work — and what would break it

The market is paying 2.6x revenue for LFST, up 69% year over year but still 84% below the 2021 peak multiple. Price-to-revenue of 2.6x That tells you the stock is no longer a broken IPO story; it is a margin-inflection story with a 2027 speed bump. The global tape supports the sector: behavioral health services names are up 53.8% over 360 days, and site-of-service themes have been bid. LFST is not in those baskets, but it is riding the same payer shift toward outpatient, lower-cost care.The bull case is straightforward: 20-30 de novos a year, 1-2 tuck-ins a quarter, a new state like Iowa, and a clinician model that still has low-single-digit share of a fragmented market. The expansion is small today but proves the playbook. If the EHR rollout goes well, 2028 could see revenue growth reaccelerate toward the mid-teens with margins still expanding. The bear case is that the EHR drag lingers, retention never improves, and specialty stays too small to move the needle. For now, the burden of proof is on execution — and the stock is close enough to its high that the next two quarters will matter.